Company Description
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.
The company’s technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging.
Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.
It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation.
The company was incorporated in 2015 and is based in Richmond, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 26, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Kristen Fortney |
Contact Details
Address: 1445A South 50th Street Richmond, California 94804 United States | |
| Phone | 510 806 1445 |
| Website | bioagelabs.com |
Stock Details
| Ticker Symbol | BIOA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001709941 |
| Employer ID | 47-4721157 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kristen Fortney, Ph.D. | Chief Executive Officer, President and Director |
| Dov Goldstein, M.D. | Chief Financial Officer |
| Eric Morgen, M.D. | Chief Operating Officer and Director |
| Paul Rubin, M.D. | Chief Medical Officer |
| Jean-Pierre Garnier, Ph.D. | Chair of the Board |
| Michael Davidson, M.D. | Director |
| Patrick Enright | Director |
| James Healy, M.D., Ph.D. | Director |
| Rekha Hemrajani | Director |
| Vijay Pande, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 30, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 26, 2024 | 424B4 | Prospectus |